CONCLUSIONS: The use of DCV is likely to have a short term impact on the INHS budget increasing resources use compared to the sole use of INF-α+RBV+SOF. However, a trend of reduction of the costs increase is observed due to the management of health states and adverse events which may lead to the possibility to reduce costs in the long term.
showing the cost increase for health services to manage HCV positive patients, leading to the conclusion that a lack of treatment of the pathology would lead to an increase of the disease burden due to HCV induced pathologies and the related worsening of the health condition of HCV positive patients [6] [7] [8] [9] . Among HCV genotypes, genotype 3 is associated with higher HCC incidence and with accelerated fibrosis progression [10, 11] , and only two treatments are recommended by
Background
Infections due to Hepatitis C Virus (HCV) represent a global health problem, affecting patients worldwide [1] with different prevalence and incidence among countries [2] [3] [4] . They may progress to chronic cirrhosis, hepatocellular carcinoma (HCC), hepatic decompensation and may lead to liver transplant [5] . The economic and social impact of the disease was investigated in different contexts, 
Budget impact analysis of the use of daclatasvir in Italy for the treatment of Hepatitis C Virus (HCV) genotype 3 patients
the Guidelines of the European Association for the Study of Liver for the treatment of HCV genotype 3 infected patients with compensated cirrhosis [12] : sofosbuvir (SOF) + daclatasvir (DCV) + ribavirine (RBV) for 24 weeks and peg interferon α (INF-α) + RBV + SOF for 12 weeks. Due to the high cost of new HCV antiviral treatments and in absence of scientific evidence about their economic impact on the Italian National Health Service (NHS), the study presented aimed at evaluating the impact on the budget of the Italian NHS of the use of daclatasvir for the treatment of HCV genotype 3 infected patients compared with the sole use of INF-α + RBV + SOF.
Materials and Methods
An analytical decision model was implemented to forecast the impact on the budget of the Italian NHS of the use of DCV in a five year time horizon for the treatment of HCV positive patients [13] .
The patients eligible to antiviral treatment were those with a fibrosis rate of 3 and 4 (F3 and F4), as recommended by the Italian NHS. The number of eligible patients was estimated using published prevalence and incidence data, as reported in Table I . Two scenarios were structured based on the recommendations of the guidelines of the European Association for the Study of Liver [12] . In details the only two treatments recommended for cirrhotic genotype 3 HCV infected patients were considered in two scenarios, one not considering the use of DCV, therefore having a 100% market share of INF-α + RBV + SOF for 12 weeks from 2015 to 2019 (scenario 1); the second one introducing in the base case scenario SOF + DCV + RBV for 24 weeks with the following annual market shares: 50% in 2015 and 2016, 55% in 2017 and 2018, and 60% in 2019 (scenario 2). The market shares were based on experts' opinions. Patients enter the model in one of the following health states [15] : F3 (60%), F4 (16%), decompensated cirrhosis (3%), HCC (19%), liver transplant (2%). Each year patients may change their health states with probabilities based on previously published works [18, 19] , as presented in Table II . Every annual cycle a percentage of patients, equal to the effectiveness of the antiviral treatment, reach a sustained virologic response (SVR). During the first year of treatment patients may experience treatment related adverse events (anemia and rash) with rates derived from literature. The effectiveness (SVR at 12 weeks after the end of the treatment) and adverse events rates are reported in Table III . Due to lack of data concerning the effectiveness and the efficacy of the treatments among patients affected with decompensated cirrhosis, HCC and eligible for liver transplant, the same effectiveness observed in patients with fibrosis stages 3 and 4 was considered. The costs considered within the model are those of the antiviral therapy, direct medical costs for the management of the health state The cost of the antiviral therapies considered were based on the price published in the Official Gazette of the Italian Medicines Agency [26] [27] [28] [29] . The costs of the management of adverse events were calculated using an activity based costing approach, through interviews with clinical experts and are therefore based on the Italian real clinical practice. The cost of death was calculated by multiplying by 12.5 the average cost of 3 months in health states F3 and F4 [30] . The costs considered are reported in Table IV . Univariate and multivariate sensitivity analyses were performed to test the robustness of the results. The parameters changed were the cost of DCV (±10%); the effectiveness of DCV (-5%) and the number of patients eligible for antiviral treatment (±10%). The results of the analysis are reported in Table V. The use of DCV would lead to an increase of the costs for the Italian NHS in the five years considered in the analysis. In details, the costs increase is due to the cost of treatment, while the costs related to the management of patients conditions in terms of health state and to the management of the adverse events decrease in the first year (-3,258 €), increase in year 2 (+ 43,215 €) and exponentially decrease in the last three years of the analysis (-73,254 €, -179,154 € and -9,203,706 €, respectively). The total impact on the budget of the Italian NHS increase, compared to the previous year in the second and third year (+ 0.22% and + 9.43%) and decrease in the last two years (-0.45% and -29.63%). The sensitivity analysis results are reported in 
